An open-label pilot study to investigate the efficacy of apremilast in the treatment of central centrifugal cicatricial alopecia (CCCA)

"The purpose of this study is to see if the use of apremilast has an effect on the symptoms and progression of central centrifugal cicatricial alopecia (CCCA). Apremilast is an oral PDE4 inhibitor that has anti-inflammatory properties. It inhibits several substances involved in inflammation within the body. Apremilast is FDA approved for the treatment of another condition, moderate to severe psoriasis and psoriatic arthritis. Apremilast is not FDA approved for the treatment of CCCA.

Inclusion Criteria:

- Females of African ancestry >18 years of age at the time of screening

- Clinical diagnosis of mild to moderate CCCA (central centrifugal cicatricial alopecia)

Conditions:
• Hair loss
• CCCA
• Central centrifugal cicatricial alopecia